Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of advanced non-squamous NSCLC with EGFR activating mutations

On 28 April 2016, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product bevacizumab (Avastin). The marketing authorisation holder for this medicinal product is Roche Registration Limited.

The CHMP adopted a new indication as follows:

"Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations." Read more here.